BREAST CANCER

Two peer-reviewed publications cite ProSense cryoablation FDA authorization and ASBrS guidelines, and extend its use to axillary lymph node disease.

The FDA has granted fast track designation to ETX-19477, an oral PARG inhibitor, for BRCA-mutated, HR+/HER2– unresectable or metastatic breast cancer.

A guide to breast cancer biomarker testing, from ER/PR and HER2-low status to PIK3CA, AKT1, and ESR1 mutations across diagnosis and disease progression.

The multicenter PRO B trial found that weekly ePRO monitoring with alert-based nurse contact reduced fatigue vs usual care in metastatic breast cancer.

A secondary analysis of the phase 3 RxPONDER trial found that premenopausal women with low baseline AMH did not benefit from added chemotherapy vs endocrine therapy alone.

A multimodal deep learning model trained in the NSABP B-42 trial and validated in TAILORx predicted late distant recurrence risk in HR-positive breast cancer.

Neoadjuvant inetetamab plus pyrotinib and chemotherapy achieved a 60.2% total pathologic complete response rate in the phase 2 neoPICD trial.

Five-year SENOMAC trial results show omitting completion axillary dissection preserves survival and significantly reduces arm morbidity, says Jana de Boniface, MD, PhD.

Large Ontario cohort study finds lifetime breast and ovarian cancer risk varies sharply by BRCA1/BRCA2 test result, including in those with inconclusive or negative findings.

Javier Cortés, MD, PhD, discusses the final KEYNOTE-522 analysis, showing pembrolizumab plus chemotherapy sustains long-term survival benefit in early-stage TNBC.

Neo-CheckRay shows iSBRT plus durvalumab boosts pCR in high-risk ER+/HER2− breast cancer, especially PD-L1–negative “cold” tumors, with higher immune toxicity.

Sara Hurvitz, MD, discusses VIKTORIA-1 data on gedatolisib in PIK3CA-mutant HR+/HER2- breast cancer, following the drug's recent FDA approval.

Erika Hamilton, MD, discusses HER2CLIMB-05 data showing tucatinib plus HP maintenance extends PFS in HER2+ breast cancer, including brain metastases.

NCCN now prefers gedatolisib plus fulvestrant, with or without palbociclib, for PIK3CA wild-type HR+/HER2– metastatic breast cancer after endocrine therapy.

Digital app-based therapy helps breast cancer survivors reduce anxiety over 12 months; however, depression gains lagged.

WinPro trial shows adding micronized progesterone to pre-surgery letrozole fails to boost Ki67 suppression in ER+/PR+ breast cancer, but may ease hot flushes.

OSU researchers use youth-shaped, AI-assisted messaging to raise young women's awareness that alcohol increases breast cancer risk, testing real change.

Erica Stringer-Reasor, MD, of UAB, discusses gedatolisib's FDA approval, its dual PI3K/mTOR mechanism, and what's next in HR+/HER2– breast cancer care.

Large genomic study shows BRCA2 breast cancers rapidly lose RB1, resisting CDK4/6 therapy; PARP inhibitors may work better and move to first line.

During a live event, Ruta Rao, MD, and participants discussed how the redefined HER2 spectrum is reshaping first antibody-drug conjugate selection in HR+/HER2– metastatic breast cancer.

AI-built social posts aim to raise young women’s awareness that alcohol increases breast cancer risk, while a trial tracks drinking habits.

Five-year WSG TP-II results suggest chemo-free endocrine therapy with dual HER2 blockade matches paclitaxel, with fewer severe side effects.

INVINCIBLE-4 restarts testing intratumoral INT230-6 before neoadjuvant pembrolizumab chemotherapy in early TNBC, aiming to boost pCR while reducing severe adverse effects.

National BRFSS study reveals SOGI adults lag in cervical and breast cancer screening; gaps are linked to insurance, access, and stigma.

Phase 3 VIKTORIA-1 results show that gedatolisib combinations extend progression-free survival in PIK3CA-mutated breast cancer, with strong response rates and manageable stomatitis.